Global Pharma no longer threatened by US price controls
The global Healthcare sector has begun to rally hard after hitting an all-time low in terms of its recommended weight relative to benchmark. It had previously been ignored because it doesn’t fit well into the current debate about growth vs value. We think it is time for another look, chiefly because the risk of price controls on US prescription drugs is much lower than previously feared. There is no time for Congress to consider this legislation before the run-up to the mid-term elections, and politicians may find that public opinion has changed after the success of anti-Covid vaccines.